Table 1.
Efficacy of different antiangiogenic drugs in advanced gastric cancer
| Drugs | n | Median PFS (months) | Median OS (months) | ORR (%) | SD (%) | DCR (%) | Reference |
|---|---|---|---|---|---|---|---|
| Sunitinib | 78 | 2.3 | 6.8 | 2.6 | 32.1 | 34.7 | 77 |
| Regorafenib vs placebo | 147 | 2.6 vs 0.9 | 5.8 vs 4.5 | \ | \ | \ | 78 |
| Ramucirumab vs placebo | 355 | 2.1 vs 1.3 | 5.2 vs 3.8 | 3.4 vs 2.6 | 45.4 vs 20.5 | 48.8 vs 23.1 | 60 |
| Apatinib vs placebo | 267 | 2.6 vs 1.8 | 6.5 vs 4.7 | 2.8 vs 0 | 42.1 vs 8.8 | 44.9 vs 8.8 | 18 |
| Sorafenib + oxaliplatin | 40 | 3 | 6.5 | 2.8 | 47.2 | 50.0 | 79 |
| Bevacizumab + chemotherapy vs placebo + chemotherapy | 517 | 6.7 vs 5.3 | 12.1 vs 10.1 | 46.0 vs 37.4 | 29.9 vs 30.3 | 75.9 vs 67.7 | 80 |
| Ramucirumab + paclitaxel vs placebo + paclitaxel | 665 | 4.4 vs 2.9 | 9.6 vs 7.4 | 27.9 vs 16.1 | 52.1 vs 47.5 | 80.0 vs 63.6 | 81 |
| Ramucirumab + FOLFOX vs placebo + FOLFOX | 168 | 6.4 vs 6.7 | 11.7 vs 11.5 | 45.2 vs 46.5 | 39.3 vs 20.2 | 84.5 vs 66.7 | 82 |
Notes: “\’’ not available. Because there are few targeted drugs for gastric cancer, this summary chooses Phase II or III trials of antiangiogenic drugs with or without chemotherapy in advanced gastric cancer. In terms of comparison, the standard is based on their ability to prolong PFS, OS, or control disease compared to its own control group.
Abbreviations: DCR, disease control rate; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; SD, stable disease.